TY - JOUR
T1 - Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children
AU - Borkowsky, William
AU - Stanley, Kenneth
AU - Douglas, Steven D.
AU - Sophia, Lee
AU - Wiznia, Andrew
AU - Pelton, Stephen
AU - Yogev, Ram
AU - McIntosh, Kenneth
AU - Nachman, Sharon
N1 - Funding Information:
Financial support: supported in part by the Pediatric AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases, the Pediatric/Perinatal HIV Clinical Trials Network of the National Institute of Child Health and Human Development, Abbott Laboratories, Boehringer-Ingelheim Pharmaceuticals, Bristol-Myers Squibb, and Glaxo-Wellcome. This study received financial support from NIH grant AI-41110. a Members of the Study Team are listed after the text.
Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - The response of 40 immunologic parameters was studied for 147 clinically stable, protease inhibitor-naive, human immunodeficiency virus (HIV)-infected children aged 2-17 years when antiretroviral therapy was changed to either a dual nucleoside analogue regimen or a protease inhibitor-containing regimen. Immunologic response to therapy, as measured by lymphocyte subsets, 3-color flow cytometric measures, and lymphoproliferative assays, were investigated for changes in weeks 44 and 48. The most significant changes after baseline that were associated with the administration of a protease inhibitor- containing regimen were seen for percentages of CD8+/CD38+/HLA-DR+, CD8+/CD95+/CD28-, and CD8. The percentages of CD8+/CD38+/ HLA-DR+ and CD8+/CD95+/CD28- decreased from baseline medians of 33% and 46% to medians of 18% and 30% at week 44 (P <.0001 for both). Median CD4 cell count increased 168 cells/μL (from 694 cells/μL to 862 cells/μL; P = .02) by week 48 in this clinically stable population. Changes in lymphoproliferative responses to HIV antigens and recall antigens did not increase over time and between groups.
AB - The response of 40 immunologic parameters was studied for 147 clinically stable, protease inhibitor-naive, human immunodeficiency virus (HIV)-infected children aged 2-17 years when antiretroviral therapy was changed to either a dual nucleoside analogue regimen or a protease inhibitor-containing regimen. Immunologic response to therapy, as measured by lymphocyte subsets, 3-color flow cytometric measures, and lymphoproliferative assays, were investigated for changes in weeks 44 and 48. The most significant changes after baseline that were associated with the administration of a protease inhibitor- containing regimen were seen for percentages of CD8+/CD38+/HLA-DR+, CD8+/CD95+/CD28-, and CD8. The percentages of CD8+/CD38+/ HLA-DR+ and CD8+/CD95+/CD28- decreased from baseline medians of 33% and 46% to medians of 18% and 30% at week 44 (P <.0001 for both). Median CD4 cell count increased 168 cells/μL (from 694 cells/μL to 862 cells/μL; P = .02) by week 48 in this clinically stable population. Changes in lymphoproliferative responses to HIV antigens and recall antigens did not increase over time and between groups.
UR - http://www.scopus.com/inward/record.url?scp=0033912755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033912755&partnerID=8YFLogxK
U2 - 10.1086/315672
DO - 10.1086/315672
M3 - Article
C2 - 10882586
AN - SCOPUS:0033912755
VL - 182
SP - 96
EP - 103
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 1
ER -